Indivior Pharmaceuticals, Inc. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Indivior is the market leader in long-acting injectable medications for opioid use disorder (OUD), with core products SUBLOCADE and SUBOXONE Film. The Company completed a redomiciliation to the United States on January 26, 2026. As of July 28, 2026, there were 118,013,649 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $343 million | $302 million | $660 million | $568 million |
| Gross Profit | $294 million | $250 million | $570 million | $472 million |
| Gross Margin | 85% | 83% | 86% | 83% |
| Operating Income | $160 million | $72 million | $297 million | $138 million |
| Net Income | $122 million | $18 million | $211 million | $65 million |
| Diluted EPS | $0.98 | $0.14 | $1.67 | $0.52 |
| Operating Cash Flow (YTD) | $220 million (vs. $233 million YTD 2025) | |||
| Cash & Equivalents | $222 million (as of June 30, 2026) | |||
| Long-Term Debt | $487 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 14% in Q2 and 16% YTD, driven primarily by a 22% increase in U.S. SUBLOCADE sales due to volume growth and favorable price mix.
- Profitability Surge: Net income increased significantly (578% in Q2) due to revenue growth, reduced operating expenses, and the absence of a prior-year inventory write-down ($10 million in 2025).
- Expense Reduction: Operating expenses decreased 25% in Q2 and 18% YTD. SG&A dropped 23% due to headcount reductions and cost savings initiatives. R&D dropped 42% following the decision to cease Phase 3 development of INDV-6001 and not advance INDV-2000.
- Debt Refinancing: In March 2026, the Company issued $500 million in Convertible Senior Notes due 2031 and used proceeds to repay $333 million of prior debt, resulting in an $18 million loss on debt extinguishment YTD.
- Share Repurchases: The Company repurchased $300 million of stock YTD (including a $175 million accelerated share repurchase in Q2), reducing share count.
Guidance, Outlook, and Risks
- Merger with Supernus: On August 1, 2026, Indivior entered into a merger agreement with Supernus Pharmaceuticals. The transaction is expected to close in Q4 2026. Indivior will be renamed Supernus Pharmaceuticals, Inc. A special cash dividend of $1,000 million is planned for Indivior shareholders, funded by a new $650 million term loan facility.
- Liquidity: The Company maintains negative working capital due to the timing of rebate payments versus collections. Management believes cash, investments, and operating cash flow are sufficient for the next 12 months.
- Litigation:
- Opioid Litigation: Settlements with municipalities and tribes are ongoing; $56 million is accrued for these settlements.
- Dental MDL: Approximately 1,967 cases involving 26,307 plaintiffs allege dental injury from SUBOXONE Film. No loss estimate can be made at this time.
- U.K. Shareholder Claims: Multiparty action regarding alleged product-hopping; first trial on liability scheduled for Q4 2028.
- R&D Strategy: The Company is not currently pursuing any pipeline activities following the cessation of INDV-6001 and INDV-2000.
Investor Verification Checklist
- Merger Completion: Verify the status of regulatory approvals and stockholder votes required for the Supernus merger.
- Dividend Funding: Confirm the execution of the $650 million senior secured term loan facility intended to fund the $1,000 million special dividend.
- Litigation Exposure: Monitor developments in the Dental MDL and U.K. shareholder claims, as no loss estimates are currently provided.
- Rebate Timing: Assess the impact of rebate payment timing on working capital and liquidity, given the negative working capital position.
- Convertible Notes: Review the terms of the 0.625% Convertible Senior Notes due 2031, specifically the conversion price ($41.66) and potential dilution.